Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

NCT07547930 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Eye Disease, TED
Graves Ophthalmopathy
Graves Orbitopathy

Interventions

DRUG: Tofacitinib

Sponsor

The First Affiliated Hospital of Xiamen University